Pyr-AI
Pyr-AI, also known as 2-pyrrolidinylindane (2-PYI), is a stimulant drug of the 2-aminoindane family. It is the analogue of 2-aminoindane (2-AI) in which the amine has been replaced with a pyrrolidine group. The drug has been described as having strong and long-lasting amphetamine-like effects in rodents. Other 2-aminoindanes like 2-AI itself and NM-2-AI are known to act as potent monoamine releasing agents and reuptake inhibitors. Pyr-AI was first described in the scientific literature by 1973.
 | |
| Clinical data | |
|---|---|
| Other names | 2-PYI; 2-Pyrrolidinylindane; 1-(2-Indanyl)pyrrolidine; Compound 10j |
| Drug class | Stimulant |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C13H17N |
| Molar mass | 187.286 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pyr-AI, also known as 2-pyrrolidinylindane (2-PYI), is a stimulant drug of the 2-aminoindane family.[1] It is the analogue of 2-aminoindane (2-AI) in which the amine has been replaced with a pyrrolidine group.[1] The drug has been described as having strong and long-lasting amphetamine-like effects in rodents.[1][2] Other 2-aminoindanes like 2-AI itself and NM-2-AI are known to act as potent monoamine releasing agents and reuptake inhibitors.[3][4] Pyr-AI was first described in the scientific literature by 1973.[1][2]
See also
[edit]References
[edit]- ^ a b c d Brandt SD, Braithwaite RA, Evans-Brown M, Kicman AT (2013). "Aminoindane Analogues". Novel Psychoactive Substances. Elsevier. pp. 261–283. doi:10.1016/b978-0-12-415816-0.00011-0. ISBN 978-0-12-415816-0. Retrieved 2 November 2025.
A 'strong amphetamine-type activity' has been reported for the pyrrolidine derivative of 2-AI (26, Fig. 11.10) [41] and 'a long duration' of activity was observed at the 10mg/kg dose in mice. Details about the procedure were not provided but neuropharmacological screenings were based on observational methods [48]. A piperidine derivative (27, PIP-AI), on the other hand, showed analgesic properties comparable to meperidine [41].
- ^ a b Solomons E, Sam J (December 1973). "2-Aminoindans of pharmacological interest". Journal of Medicinal Chemistry. 16 (12): 1330–1333. doi:10.1021/jm00270a004. PMID 4765859.
- ^ Luethi D, Liechti ME (April 2020). "Designer drugs: mechanism of action and adverse effects". Archives of Toxicology. 94 (4): 1085–1133. Bibcode:2020ArTox..94.1085L. doi:10.1007/s00204-020-02693-7. PMC 7225206. PMID 32249347.
- ^ Halberstadt AL, Brandt SD, Walther D, Baumann MH (March 2019). "2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α2-adrenergic receptors". Psychopharmacology. 236 (3): 989–999. doi:10.1007/s00213-019-05207-1. PMC 6848746. PMID 30904940.
External links
[edit] | This psychoactive drug-related article is a stub. You can help Wikipedia by adding missing information. |